JUNS · Jupiter Neurosciences, Inc.
$2.58
-0.20 (-7.19%)
At close · Oct 22
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.14M
Shares
770,081
Volume · Oct 22
10.15K
Avg daily vol (54 sessions)
1.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.58
Open$2.80
Day$2.55–2.80
52W close$2.42–127.50
Avg vol 30d72K
Short int35K · 4.6% float · 1.0d
Short vol13%
DataDec 2024–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$40,448
Trailing 12 months
Net income (TTM)
−$9.20M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-40,873.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.6%
Latest settlement · 1.0 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−89%
below
Price vs 50-day avg
−26%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−91%
trailing
YTD return
−97%
this year
Relative strength
−97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+30% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.60% of float · ▼ -32.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
13 holders — near 1-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
Gross margin
81%
EPS growth
−213%
Y/Y
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
13.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−89%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+30% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.60% of float · ▼ -32.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
13 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 0%
Range high $128
vs 200-day avg -89%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JUNS
this stock
Jupiter Neurosciences, Inc.
|
$2.14M | — | — | — | 4.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +18.0% | +46.2% | 31.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$98.14B | +587.1% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.95B | +6.1% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JUNS | -17.8% | -10.6% | -91.2% | +5.7% | -96.6% |
| SPY | -1.0% | -0.4% | +6.0% | +0.2% | +12.0% |
| vs SPY | -16.8% | -10.2% | -97.2% | +5.6% | -108.7% |